Yann Barrault

DTx FRANCE 2024 Proud to be International Partner of #DTxFrance 2024, the French and European event on Digital Therapeutics #DTx https://lnkd.in/eMm8Y6M7. With the adoption of #Pecan, France is on its way to becoming a #DTxNation and a new reference for Digital Therapeutics and patient-facing digital health technologies at European and international level. Mathilde Pasko Kamal Kishor Kénnètth Jósèph, PharmD, MBA Kyle Dardashti

11

💊 [Biomedicines Market : dazzling growth🚀] The biomedicine market is expected to reach €320 billion by 2025! Biomedicines accounted for more than €200 billion in 2019, or around 24.3% of the global pharmaceutical market 🌍 Access to these new therapies continues to grow, with 690 biomedicines sold in Europe and 363 in France. 💡 Want to know more about biomedicines & bioproduction market ? To highlight the French industry, France BioLead is launching National Day of Biomanufacturing and Biomedicine on 5 July 2024. 📅 See you in Toulouse for an unmissable event organized by Just - Evotec Biologics, GTP Bioways, Flash BioSolutions and TWB, with the support of Bio'Occ : projet Biothérapie et Bioproduction en Occitanie, Eurobiomed and Leem. Details : https://lnkd.in/dRKSUcFw #ATMP #Biomedicaments #biotherapies #biomedicines #biotechnology #JNBB2024

17

𝗝𝗼𝗶𝗻𝘁 𝗥&𝗗 𝗲𝗳𝗳𝗼𝗿𝘁𝘀 𝘄𝗶𝘁𝗵 𝗿𝗲𝗴𝗮𝗿𝗱𝘀 𝘁𝗼 𝗰𝗼-𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀 are considered „crucial“ for (European) SME Pharma and Biopharma companies’ future success, claims Telma Costa 🇪🇺 … to make a few steps in the right direction Europharm smc and Alain Verrijdt foster relationships through their annual business meeting (this year in #zagreb)… and collaboration proposals like from maurienne will from Will Pharma reiterate the need/demand for that from CEOs. 💡💡💡 But there is more, that is on the CEOs minds. And therefore, in Zagreb 🇭🇷 theses three (Manfred Stadler, Telma Costa, Alain Verrijdt) advocate for more transparency concerning strategic topics in Pharma and Biopharma SMEs as an input, inspiration and as a decision making basis have promoted our CEO survey. 𝗪𝗵𝗲𝗿𝗲 𝘁𝗼 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲? The annual CEO survey is again online: https://lnkd.in/gj97_VRa #europharm #healthcarestrategy #ceoreport #vinc

16

💊 [Bioproduction – French CDMO landscape] France is the European leader in terms of the number of production sites. 31 French biomanufacturing sites belong to 19 CDMOs! The French CDMOs are divided according to the type of batches produced: - 6 sites for clinical and commercial batches - 7 sites for preclinical and clinical batches - 18 sites for preclinical, clinical and commercial batches   🔔💡 Not to be missed! To highlight the French industry, France BioLead is launching National Day of Biomanufacturing and Biomedicine on 5 July 2024. 📅 See you in Toulouse for an unmissable event organized by Just - Evotec Biologics, GTP Bioways, Flash BioSolutions and TWB, with the support of Bio'Occ : projet Biothérapie et Bioproduction en Occitanie, Eurobiomed and Leem. 🔬 #Biotechnology #Biomedicines #Bioproduction #Biomanufacturing #JNBB2024

48

NEW STUDY - BNT162b2 shots associated with increased risk for psoriasis, colitis and polymyalgia rheumatic. Following injection with BNT162b2, there is an increased risk of developing immune-mediated conditions, including psoriasis across all age groups (41%-69%), colitis in individuals under 65 years (38%-93%), vitiligo in those aged 45-64 years (182%), and polymyalgia rheumatica in individuals aged 65 and older (112%). This retrospective cohort study was based on Clalit Health Services (CHS) comprehensive database and compared the rates of immune-mediated diagnoses among BNT162b2 injected versus unvaccinated individuals. #MFScholar https://lnkd.in/gdtArU2Q Nicolas Hulscher, MPH

53

4 commentaires

📢📄 [#PressRelease] May 30, 2024: Lys Therapeutics Announces Significant Scientific Advances in Neurodegenerative and Neurovascular Diseases With several #publications and oral #presentations at international medical conferences, Lys Therapeutics consolidates its scientific advances and demonstrates the quality of its research in the fields of #Stroke, #Parkinson's disease, and #MultipleSclerosis.   Lyon & Caen, France, May 30, 2024 – Lys Therapeutics, a pioneering French biotechnology company revolutionizing the treatment of patients with neurodegenerative and neurovascular diseases, today announces a series of scientific advances made public during the first half of 2024. These include six events (plenary presentations, oral communications, publications, and posters) where Lys Therapeutics presented major preclinical results in its two strategic areas: emergency medicine (including strokes) and neurodegenerative diseases (such as Parkinson's disease and multiple sclerosis). More information on https://lnkd.in/gwWwQ2rR

33

1 commentaire

Tribun Health, a major player in software solutions for digital pathology, has announced its selection among the winners of the i-Nov Wave 11 competition organized by Bpifrance, as part of the France 2030 plan. This competition aims to support the accelerated emergence of innovative companies that are leaders in their field. Tribun Health’s image management software CaloPix® represents a significant advancement in anatomopathology. Tribun Health’s project, “Pathomix®,” strives to broaden diagnostic product offerings, fostering a seamless integration between healthcare services and advancements in research and pharmaceutical development. The project's aim is to empower pathology’s role in precision diagnostics by providing advanced tools for the consolidation, enhancement, and exploitation of real-world data. At the heart of this initiative is the development of an advanced data query module, allowing healthcare facilities to pinpoint specific data for secondary use while adhering to GDPR and HIPAA regulations. #digitalpathology #pathologynews

36

🧬 Are you involved in advanced therapies R&D or related solutions? 🤝 Do you want more visibility to connect with the right investors or partners?   ❗ Then join MEDVIA and BioWin at Advanced Therapies in Belgium, where we focus on cell, gene and other novel therapies 🔥 Register now for a 30% reduction on the ticket fee!   ➡ 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗕𝗲𝗹𝗴𝗶𝘂𝗺 📅 𝟭𝟱 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟰 🗺 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗘𝗰𝗼𝗹𝘆𝘀 𝗩𝗶𝗹𝗹𝗮𝗴𝗲, 𝗡𝗮𝗺𝘂𝗿   WHAT CAN YOU EXPECT? 🧫Plenary session on Belgium’s position in the European ATMP landscape 🧫Debate on major challenges faced by developers of advanced therapies 🧫Presentation of available financing mechanisms 🧫B2B networking & matchmaking 🧫Advanced Therapies Expertise Corner   Sign up to pitch at the event if you have: 🗨️ Project ideas in need of collaboration 🗨️ A track record of joint projects 🗨️ Broad development ideas requiring diverse skills and partners   𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲 👉🏽 https://lnkd.in/g8CyafGD 𝗣𝗶𝘁𝗰𝗵𝗶𝗻𝗴 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀 👉🏽 https://lnkd.in/e2Tm4NDA #ATMP #AdvancedTherapies #celltherapy #genetherapy #NovelTherapies #healthinnovation #healthtech #medtech #biotech #digitalhealth

14

1 commentaire

Former Italian Prime Minister Enrico Letta recently released a report entitled ‘Much More Than a Market‘, as requested by the European Council in June 2023. The report stressed the key actions needed to ensure the modernisation of the European Single Market, and addressing the contemporary challenges and opportunities faced by the European Union (EU). Learn more about what this could mean for people living with rare diseases from Solène Jouan, our EU Public Affairs Manager! 🗞️ Read now: https://lnkd.in/eg2d3Xeq #Europe #RareDiseases #SingleMarket

16

[JUST RELEASED] Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2024 - https://lnkd.in/eCkW5rn Between 2017 and 2024, nine CAR-T products reached commercialization, and this number is estimated to reach double-digits by 2032. Of these, six are U.S.FDA-approved CAR-T cell therapies, each of which have received approvals in other major healthcare markets as well. The six U.S. FDA approved products include: Kymriah (tisagenlecleucel) Yescarta (axicabtagene ciloleucel) Tecartus (brexucabtagene autoleucel) Breyanzi (lisocabtagene maraleucel) Abecma (idecabtagene vicleucel) Carvykti (Ciltacabtagene autoleucel) In addition, two CAR-T therapies have received approval from the Chinese National Medical Products Administration (NMPA), Relma-cel and Yuanruida, and one CAR-T cell therapy has received approval from the Indian Central Drugs Standard Control Organisation (CDSCO), NexCAR19. The purpose of this report is to describe the current state of CAR-T cell therapies, as well as the future of the CAR-T industry landscape at large. Importantly, it describes details of the CAR-T cell therapy products approved to date, as well as late-stage CAR-T clinical trials that could lead to near-term market approvals. Ranging from small start-ups to billion-dollar companies, CAR-T companies are now proliferating in all healthcare markets worldwide. #cartcelltherapy #advancedtherapies #celltherapy

1

#Axoltis team is a French company, engaged to develop drugs to treat neurodegenerative diseases, among them #ALS (Amyotrophic lateral sclerosis).   ALS is a fatal type of motor neuron disease. It causes progressive degeneration of nerve cells in the spinal cord and brain. ALS is one of the most devastating types of disorders that affect nerve and muscle function. There are sporadic (about 90%) and familial forms. There is strong evidence for blood-brain and blood-spinal cord barrier dysfunction at the early stages of many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Since impairment of the blood-central nervous system barrier (BCNSB) / Blood Brain Barrier (BBB) occurs at very early stages of the disease, the mechanisms underlying this pathology are likely also involved in the ALS disease process. NX210c, an innovative drug developed by Axoltis Pharma, is able to restore the integrity of the BBB. A Phase II clinical trial is authorized to be launched in patients suffering ALS. www.axoltis.com

69

2 commentaires

AI is making strides in the field of oncology, particularly in its ability to detect and predict the recurrence of breast cancer with impressive accuracy. By analyzing patterns in vast datasets, including medical images, patient histories, and genetic information, AI algorithms can identify subtle signs of cancer recurrence that might elude even experienced clinicians. This capability arises from AI's power to integrate and learn from diverse data sources, allowing it to recognize complex patterns associated with the risk of recurrence. For instance, machine learning models can analyze mammograms and other imaging data to detect minute changes that might indicate the return of cancer, sometimes even before symptoms appear. The use of AI in monitoring breast cancer recurrence not only enhances diagnostic accuracy but also supports personalized treatment planning. By predicting the likelihood of recurrence, AI can help clinicians tailor follow-up care and treatment options to individual patients' risk profiles, potentially improving outcomes and reducing the burden of unnecessary treatments. Explore More Insight: https://bit.ly/4a8LXA3 #breastcancer #healthcare #amr

5

Next Speaker of the 3rd Annual ACDM Symposium on Artificial Intelligence (AI) in Clinical Trials is announced as....... The ACDM: Association for Clinical Data Management is delighted to announce that Nicolas Loiseau of Owkin will present the session “FedECA: A Federated External Control Arm Method for Causal Inference in Distributed Settings” at the AI Symposium. Non-randomized or single-arm clinical trials might be easier to conduct compared to randomized clinical trial, but they are less informative due to the lack of a control cohort to benchmark the experimental drug’s efficacy. One solution is to use an external control arm (ECA), a cohort of control patients collected from data external to a clinical trial. ECA analysis can inform early clinical development of experimental drugs, when used as a comparator to an experimental arm, providing evidence on the drug’s efficacy in non-randomized settings. To overcome the challenges of implementing ECA analysis, this presentation will cover promising approaches fuelled by Machine Learning models to align the clinical profiles of patients from both the experimental and external arms to provide an unbiased estimation of efficacy. The AI Symposium will take place from 24-25 June 2024 in Basel, Switzerland. Find out more and book your place here: https://lnkd.in/ef-cQ9SN Premier Sponsors: Medidata Solutions, eClinical Solutions, CluePoints, Saama ACDM Board: Robert King, Sverre Bengtsson, Jo Marshall, Nina Reyes, Eva Alder, Richard Davies, Nicola Götz, Anita Kratchmarov, Ashley Howard, Amelie Spieser AI Symposium Steering Group: Richard Davies, Ashley Howard, Marcus Schwabedissen, Tim Armitage, Rob Nichols #clinicalresearch #clinicaltrials #clinicaldatamanagement #clinicaloperations #edc #ACDM #AI #artificialintelligence

60

2 commentaires

TLDR Biotech for June 28 - July 1 𝐓𝐡𝐞 𝐆𝐨𝐨𝐝 ✅ 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬: Pierre Fabre's Obgemsa (viberon) passes EMA vibe check, approved for overactive bladder syndrome 💊 + 2 more stories 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Eli Lilly signs $140M radiopharma deal with Radionetics ☢️ + 3 more stories 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Boehringer Ingelheim, Gubra begin Ph1 for novel "first-in-class" obesity treatment 🧪 + 3 more stories 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Freeflow Ventures closes $90M early-stage venture fund 💰 + 2 more stories 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬: Veranova invests $30M into ADC manufacturing facility 🏭 + 1 more story 𝐈𝐏𝐎𝐬: Artiva Biotherapeutics rides cell therapy autoimmune wave to an IPO (this time for real?) 📈 𝐋𝐚𝐰𝐬𝐮𝐢𝐭𝐬: GSK settles another Zantac suit ⚖️ 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Merck & Co. and Orion expand drug discovery partnership 🤝 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐀𝐜𝐜𝐞𝐬𝐬: FDA announces cisplatin no longer in short supply 🏥 𝐓𝐡𝐞 𝐁𝐚𝐝 ❌ 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: TRACON Pharmaceuticals drops sarcoma asset after Ph2 miss 📉 𝐋𝐚𝐲𝐨𝐟𝐟𝐬: Dexcom lays off 535 staffers in San Diego 😢 + 3 more stories 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩: Bristol Myers Squibb ends $650M ADC partnership with Eisai 💔 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐀𝐜𝐜𝐞𝐬𝐬: Walgreens’ plan to close stores may impact underprivileged communities 🏪 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲: FDA urged to be more transparent about CRLs after recent spate of related rejections 🔍 𝐓𝐡𝐞 𝐔𝐠𝐥𝐲 👹 𝐂𝐫𝐢𝐦𝐢𝐧𝐚𝐥 𝐀𝐜𝐭����: Cassava Sciences drama continues with internal investigation 🕵️ 𝐋𝐚𝐰𝐬𝐮𝐢𝐭𝐬: J&J talc subsidiary bankruptcy plan continues despite restraining order attempt ⚖️ 𝐏𝐨𝐥𝐢𝐭𝐢𝐜𝐬 & 𝐏𝐨𝐥𝐢𝐜𝐲: FTC targets multiple "bogus" Teva Pharmaceutical patents 🎯 𝐖𝐢𝐭𝐡𝐝𝐫𝐚𝐰𝐚𝐥𝐬 & 𝐑𝐞𝐜𝐚𝐥𝐥𝐬: FDA issues Class 1 recalls for multiple ventilator manufacturers 🚨 Read the full newsletter here: https://lnkd.in/gfKrb24F Or subscribe to get it straight to your inbox: https://lnkd.in/gecXctqM #tldrbiotech #pharmanews #biotechnews

5

[STRENGTHENING FRANCE'S POSITION IN PHARMACEUTICAL PRODUCTION]   🌟 France, historically a pharmaceutical leader, faces the challenge of competitiveness. With only 48 out of 508 drugs produced in Europe between 2017 and 2022 (Leem), our position is considered at risk. To ensure French sovereignty and competitiveness, securing the sourcing of raw materials (API and excipients) will be essential.   As a French pharmaceutical lactose producer, we will contribute to securing the supply chain, ensuring consistent access to raw materials for French drug manufacturers. 💊   #securityofsupply #pharmaceuticallactose #distribution https://lnkd.in/eVUVZDSe

28

📄 [Press Release] – MaaT Pharma is proud to announce the successful completion of its Global Offering of 19.2 Million Euros ▪ Support from historical investors Bpifrance, Seventure Partners, Biocodex, and from the management of the Company ▪ 70% of new retail investors previously non-shareholders joined us, showcasing a strong influx of new support, with a total investment of €0.9 million ▪ Financing will enable the Company to extend its cash runway through early Q1 2025 ▪ The net proceeds from the Primary Offering will be used to fund the company’s R&D activities, covering completion of the Phase 3 trial for MaaT013 in Europe, including top-line results/primary endpoint in mid Q4 2024, continuing the pipeline development, including the initiation of Phase 3 trial activities for MaaT013 in the US and the broadening of the Phase 2b trial with MaaT033 across Europe and for working capital and other general corporate purposes, including repayment of current debts. 👉 Read the press release here: https://lnkd.in/efFj8Ube

97

2 commentaires

💊Exciting News! 💊 From June 20-21, Lionel Renaud, Senior Modeler at LYO-X, will be attending the 12th Antibody Industrial Symposium (AIS2024) in picturesque Montpellier, France! This prestigious conference brings together experts in therapeutic antibodies, recombinant proteins, and cellular immunotherapy to share the latest in research, development, and clinical advancements. We're thrilled to announce that Lionel, invited by Pierre Ferre, SVP of Preclinical Development & Corporate Operations at Compugen, will be delivering an insightful talk. He will discuss how PK/PD modeling can be a game-changer in overcoming challenges and avoiding pitfalls in therapeutic antibody development. In his presentation, Lionel will delve into:  🎯 Tackling reduced antibody exposure due to target-mediated drug disposition (TMDD)  📊 Understanding factors influencing effect duration (target turnover, antibody-target binding affinity)  ⛵ Navigating target cross-reactivity  😷 Addressing antibody immunogenicity in preclinical species Don't miss this opportunity to gain valuable insights from Lionel's expertise. Date: 21 June 2024 Time: 08:30hrs Venue: CORUM Conference Centre, Montpellier (F), Einstein Auditorium Stay tuned for updates from AIS2024! #AIS2024 #AntibodyTherapeutics #PKPDModeling #LYOX #Compugen #TherapeuticAntibodies #Immunotherapy #BiotechInnovation

16

1 commentaire

Discover how the Precellys Evolution Touch & Cryolys Evolution duo is revolutionizing preformulation processes in drug development. Take a look at Bertin Technologies latest article to uncover the efficiency and versatility of these cutting-edge instruments. #Precellys #Cryolys #SamplePrep #Innovation #EfficiencyBoost

9